Okolo Onyemaechi N, Johnson Ariel C, Yun Seongseok, Arnold Stacy J, Anwer Faiz
Department of Medicine, University of Arizona, 1501 N. Campbell Ave, Tucson, AZ 8572, USA.
University of Arizona College of Medicine, 1501 N Campbell Ave, Tucson, AZ 85721, USA.
Immunotherapy. 2017 Aug;9(9):709-714. doi: 10.2217/imt-2017-0027. Epub 2017 Aug 3.
Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which bodes a poor prognosis. When transformation includes mutations of MYC, BCL-2 and/or BCL-6, it is known as a 'double hit' or 'triple hit' lymphoma respectively. This paper presents a rare case of WM with mutations positive for MYC and BCL2, making it a case of double hit B-cell lymphoplasmacytic lymphoma with plasmatic differentiation without morphological transformation to aggressive histology like DLBCL. The paper also broadens to include discussions on current topics in the classification, diagnosis, possible causes of transformation, and treatment of WM, including transformation to double hit lymphoma. The significance of this case lies in that the presence of double hit lymphoma-like genetic mutations in WM have not been previously described in the literature and potentially such changes are harbinger of extra-nodal presentation, aggressive growth, and possibly poor prognosis, if data from other double-hit lymphoma are extrapolated.
华氏巨球蛋白血症(WM)是一种淋巴增殖性淋巴瘤,其特征为单克隆免疫球蛋白M(IgM)蛋白和骨髓浸润。其发病率很低,而转化为B细胞淋巴瘤的能力更为罕见,尤其是侵袭性弥漫性大B细胞淋巴瘤,这预示着预后不良。当转化包括MYC、BCL-2和/或BCL-6突变时,分别称为“双打击”或“三打击”淋巴瘤。本文报告了1例罕见的WM病例,其MYC和BCL2突变呈阳性,使其成为1例具有浆细胞分化的双打击B细胞淋巴浆细胞性淋巴瘤,且未向侵袭性组织学如弥漫性大B细胞淋巴瘤发生形态学转化。本文还拓展内容,包括讨论WM在分类、诊断、可能的转化原因及治疗方面的当前话题,包括转化为双打击淋巴瘤。该病例的意义在于,WM中存在双打击淋巴瘤样基因突变此前在文献中未曾描述过,并且如果外推其他双打击淋巴瘤的数据,这种变化可能是结外表现、侵袭性生长以及可能预后不良的预兆。